Lucid Diagnostics (NASDAQ:LUCD) Rating Lowered to “Sell” at Wall Street Zen

Lucid Diagnostics (NASDAQ:LUCD) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other research firms also recently weighed in on LUCD. BTIG Research raised their price target on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a report on Friday, September 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Wednesday, November 5th. Ascendiant Capital Markets boosted their price target on Lucid Diagnostics from $7.75 to $8.00 and gave the stock a “buy” rating in a research report on Monday, October 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a research note on Thursday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $3.88.

Lucid Diagnostics Price Performance

Shares of Lucid Diagnostics stock opened at $1.07 on Friday. The firm has a market cap of $147.32 million, a price-to-earnings ratio of -1.03 and a beta of 1.22. The stock has a 50-day simple moving average of $1.13 and a 200-day simple moving average of $1.16. Lucid Diagnostics has a 52-week low of $0.75 and a 52-week high of $1.80.

Lucid Diagnostics (NASDAQ:LUCD) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The company had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $1.35 million. As a group, equities research analysts predict that Lucid Diagnostics will post -0.84 earnings per share for the current year.

Insider Transactions at Lucid Diagnostics

In other Lucid Diagnostics news, Director Dennis Matheis purchased 100,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were bought at an average cost of $1.02 per share, with a total value of $102,000.00. Following the completion of the transaction, the director owned 665,443 shares in the company, valued at $678,751.86. This trade represents a 17.69% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.80% of the stock is owned by company insiders.

Institutional Trading of Lucid Diagnostics

Several hedge funds have recently added to or reduced their stakes in the business. Sprott Inc. bought a new position in Lucid Diagnostics in the 3rd quarter worth approximately $25,000. SG Americas Securities LLC acquired a new stake in shares of Lucid Diagnostics in the third quarter worth $26,000. Quadrature Capital Ltd bought a new position in Lucid Diagnostics during the second quarter worth $29,000. Berkshire Asset Management LLC PA acquired a new position in Lucid Diagnostics during the 1st quarter valued at $30,000. Finally, Traphagen Investment Advisors LLC acquired a new position in Lucid Diagnostics during the 2nd quarter valued at $34,000. Institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.